Author Interviews, Herpes Viruses, Inflammation, Vaccine Studies / 21.10.2025
ID Week 2025: Shingrix Vaccine for Shingles Associated with Fewer Heart and Brain Adverse Events
[caption id="attachment_71064" align="alignleft" width="200"]
Dr. Dehghani[/caption]
MedicalResearch.com Interview with:
Ali Dehghani, DO
Department of Medicine
University Hospitals Cleveland Medical Center / Case Western Reserve University
Presenting Author, IDWeek 2025
MedicalResearch.com: What is the background for this study?
Response: Shingles (herpes zoster) is caused by reactivation of the varicella-zoster virus, which can inflame blood vessels and the nervous system. Evidence over the past decade has linked shingles to higher risks of heart attack, stroke, and dementia—but it was unclear whether the shingles vaccine might lessen those long-term effects.
[caption id="attachment_71061" align="aligncenter" width="500"]
CDC PHIL Image[/caption]
MedicalResearch.com: What are the main findings?
Response: Using data from over 100 U.S. health systems, we followed adults age 50 and older for up to five years. We found that people who developed shingles had a 20–30% higher risk of cardiovascular events, vascular dementia, and death compared with similar adults without shingles.
Those who had received the recombinant zoster vaccine (Shingrix) before their infection had substantially lower long-term risks—about 25% fewer major cardiac events, 40% lower early mortality, and nearly 50% less vascular dementia over time.
Dr. Dehghani[/caption]
MedicalResearch.com Interview with:
Ali Dehghani, DO
Department of Medicine
University Hospitals Cleveland Medical Center / Case Western Reserve University
Presenting Author, IDWeek 2025
MedicalResearch.com: What is the background for this study?
Response: Shingles (herpes zoster) is caused by reactivation of the varicella-zoster virus, which can inflame blood vessels and the nervous system. Evidence over the past decade has linked shingles to higher risks of heart attack, stroke, and dementia—but it was unclear whether the shingles vaccine might lessen those long-term effects.
[caption id="attachment_71061" align="aligncenter" width="500"]
CDC PHIL Image[/caption]
MedicalResearch.com: What are the main findings?
Response: Using data from over 100 U.S. health systems, we followed adults age 50 and older for up to five years. We found that people who developed shingles had a 20–30% higher risk of cardiovascular events, vascular dementia, and death compared with similar adults without shingles.
Those who had received the recombinant zoster vaccine (Shingrix) before their infection had substantially lower long-term risks—about 25% fewer major cardiac events, 40% lower early mortality, and nearly 50% less vascular dementia over time.
Dr. Bradshaw[/caption]
Catriona Bradshaw MMBS(Hons), PhD, FAChSHM, FAHMS
Professor (Research), Head of Research Translation and Mentorship
and of The Genital Microbiota and Mycoplasma Group Melbourne
School of Translational Medicine, Monash University and Alfred Hospital
Principal Research Fellow at the Burnet Institute
MedicalResearch.com: What is the background for this study?
Response: One in three women globally have bacterial vaginosis (BV), a condition that causes a malodourous discharge, and associated with serious gynaecologic and obstetric sequelae (including miscarriage and preterm birth) and increases the risk sexually transmitted infections (STIs) and HIV. Women with symptoms are treated with broad-spectrum antibiotics, however, over 50% of women experience BV recurrence within 3-6 months. The recurrence rate is even higher at 60-80% among women with an ongoing regular partner. Current practice is to simply retreat women experiencing BV recurrence with the same antibiotics, which leaves them (and clinicians) frustrated and distressed.
We and others have accumulated a body of evidence to show that BV has the profile of an STI. BV-associated bacteria are detected in men in the distal urethra and on penile-skin, and couples share these organisms. However, to date, has not been recommended for BV as it is for other STIs. This is largely because men do not usually have any symptoms, and past partner-treatment trials in the 1980s and 1990s, which only used oral antibiotics for men, failed to prevent BV recurrence, which was taken as conclusive evidence against sexual transmission. Reviews of these trials have since identified their limitations.
Given the evidence of male carriage of BV-associated bacteria at two genital sites, we hypothesised that both sites needed to be targeted with antimicrobial therapy to prevent re-infection post-treatment. The aim of our study was to assess if male partner-treatment concurrently with female treatment using a combination of oral and topical antibiotics for the first time, would decrease BV recurrence over 12 weeks compared to the current standard practice of treating women only.
Prof. Chaturvedi[/caption]
Prof. Vishnu Chaturvedi, Ph.D., HCLD
Department of Pathology, Microbiology and Immunology
New York Medical College
Department of Pathology, Westchester Medical Center
Valhalla, New York,
MedicalResearch.com: What is the background for this study? How does Candida auris differ from Candida albicans, ie in clinical presentation or treatment?